Valeo Pharma Inc. (VPHIF)
OTCMKTS · Delayed Price · Currency is USD
0.0469
-0.0471 (-50.11%)
At close: Aug 29, 2024

Valeo Pharma Statistics

Total Valuation

Valeo Pharma has a market cap or net worth of 4.63 million. The enterprise value is 49.22 million.

Market Cap4.63M
Enterprise Value 49.22M

Important Dates

Earnings Date n/a
Ex-Dividend Date n/a

Share Statistics

Valeo Pharma has 98.68 million shares outstanding.

Current Share Class 98.68M
Shares Outstanding 98.68M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 19.47%
Owned by Institutions (%) n/a
Float n/a

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.12
PB Ratio -0.10
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -2.12
EV / Sales 1.27
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -16.91

Financial Position

The company has a current ratio of 0.27

Current Ratio 0.27
Quick Ratio 0.17
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF -17.59
Interest Coverage -1.05

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -26.07%
Return on Invested Capital (ROIC) -55.16%
Return on Capital Employed (ROCE) 42.98%
Revenue Per Employee 552,025
Profits Per Employee -332,185
Employee Count110
Asset Turnover 1.37
Inventory Turnover 4.22

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -70.18% in the last 52 weeks. The beta is 1.02, so Valeo Pharma's price volatility has been similar to the market average.

Beta (5Y) 1.02
52-Week Price Change -70.18%
50-Day Moving Average 0.12
200-Day Moving Average 0.27
Relative Strength Index (RSI) 42.68
Average Volume (20 Days) 6,836

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Valeo Pharma had revenue of 38.64 million and -23.25 million in losses. Loss per share was -0.26.

Revenue38.64M
Gross Profit 8.70M
Operating Income -11.74M
Pretax Income -23.25M
Net Income -23.25M
EBITDA -10.21M
EBIT -11.74M
Loss Per Share -0.26
Full Income Statement

Balance Sheet

The company has 5.16 million in cash and 51.20 million in debt, giving a net cash position of -46.04 million or -0.47 per share.

Cash & Cash Equivalents 5.16M
Total Debt 51.20M
Net Cash -46.04M
Net Cash Per Share -0.47
Equity (Book Value) -45.63M
Book Value Per Share -0.46
Working Capital -36.82M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.83 million and capital expenditures -86,149, giving a free cash flow of -2.91 million.

Operating Cash Flow -2.83M
Capital Expenditures -86,149
Free Cash Flow -2.91M
FCF Per Share -0.03
Full Cash Flow Statement

Margins

Gross margin is 22.51%, with operating and profit margins of -30.37% and -60.18%.

Gross Margin 22.51%
Operating Margin -30.37%
Pretax Margin -60.18%
Profit Margin -60.18%
EBITDA Margin -26.41%
EBIT Margin -30.37%
FCF Margin n/a

Dividends & Yields

Valeo Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -5.43%
Shareholder Yield n/a
Earnings Yield -502.45%
FCF Yield -62.92%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Valeo Pharma has an Altman Z-Score of -6.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -6.35
Piotroski F-Score 3